Among the LGDMs, the use of IVIG has only been explored in patients affected by dysferlin gene mutations (DYSF, MIM*603009) that are responsible for recessively inherited dysferlinopathy which is most pronounced in the pelvic and shoulder girdle muscles (Limb girdle muscular dystrophy R2, formerly LGMD2B), or distal myopathy with onset in gastrocnemius and soleus muscles in cases of Miyoshi myopathy (MM or MMD1), or distal myopathy with onset in the tibialis anterior (DMAT) (also referred to as DACM for distal anterior compartment myopathy) (55, 56). This evidence concerns the gene DYSF and distal myopathy.